Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730353 · ClinicalTrials.gov registry record · Phase 2
Sutent + Taxol for Advanced Esophageal Cancer
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00730353 is a Phase 2 study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 28 participants.
The verdict
NCT00730353, a Phase 2 study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.
Interventions
- DRUG Paclitaxel
- DRUG Sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730353
The ClinicalTrials.gov registry entry for NCT00730353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00730353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730353 about?
NCT00730353 is a clinical study titled "Sutent + Taxol for Advanced Esophageal Cancer". Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, a...
What is the current status of trial NCT00730353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2008-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00730353?
The interventions under investigation include: Paclitaxel (DRUG), Sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00730353?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.